A randomized phase II study of maintenance therapy with multiepitope vaccine tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM PRODIGE 63 GERCOR study)
ANNÉE
2019
AUTEURS
Neuzillet C, Hautefeuille V, Lambert A, Garcia-Larnicol ML, Vernerey D
CONGRÈS/REVUE
ESMO
ÉTUDE
Localisation
LIEN PUBLICATIONS ASSOCIÉES